Results 71 to 80 of about 2,896 (157)
A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia
The approval of ibrutinib over a decade ago introduced Bruton tyrosine kinase (BTK) inhibition as a foundational, chemotherapy-free treatment approach for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Paolo Ghia +3 more
doaj +1 more source
Introduction and objectives: BTK inhibitors (BTKis) have revolutionized the treatment landscape of chronic lymphocytic leukemia (CLL). However, a higher risk of cardiovascular toxicity is reported among CLL patients treated with BTKis. This study aims to
Débora Figueira +7 more
doaj +1 more source
Zanubrutinib-Induced Acneiform Rash in a Patient With Waldenstrom’s Macroglobulinemia
Waldenström’s macroglobulinemia is a rare lymphoproliferative disorder that can be treated with Bruton’s Tyrosine Kinase inhibitors (BTKi), including zanubrutinib.
Silvia Robuffo +6 more
doaj +1 more source
Objective To evaluate the cost-effectiveness of zanubrutinib compared to ibrutinib in the first-line treatment of chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) from the perspective of the Chinese healthcare system. Methods A three-
Ying Liu +4 more
doaj +1 more source
Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma. [PDF]
Martin-Moro F +40 more
europepmc +1 more source
Case Report: Zanubrutinib for refractory immune thrombotic thrombocytopenic purpura. [PDF]
De Angelis AD +6 more
europepmc +1 more source
Bing-Neel syndrome successfully treated with venetoclax and zanubrutinib: A case report and review of the literature. [PDF]
Jin S, Wu Y, Zhang J.
europepmc +1 more source
Respiratory adverse-event signals of four Bruton tyrosine kinase inhibitors: cross-database replication and temporal characterization in FAERS and JADER. [PDF]
Zheng Z, Zhao F, Zhao Z, Jin P.
europepmc +1 more source

